CHMP backs Xolair for severe hives PMLiVE Based on the results of a phase III trial the drug has been backed to treat CSU as a monthly subcutaneous injection in patients aged over 12 as an add-on to standard treatment with antihistamines and – in severe cases - corticosteroids. Around half of ... |
